Læknablaðið - 01.01.2014, Qupperneq 25

Bættu Lyxumia við og bættu virknina
•
•
•
NÝ
TT
LY
F!
IS
-
L
IX
-13
-12
-
0
4
GLP-1 viðtakaörvi sem hefur áhrif á
blóðsykurshækkun eftir máltíðir gefinn
1,2einu sinni á dag
Marktæk lækkun á HbA1c með greinileg
3-6áhrif á blóðsykurshækkun eftir máltíð
3-6Jákvæð áhrif á líkamsþyngdina
Heimildir: 1. Lyxumia Sérlyfjaskrártexti, 4. október 2013. 2. Vidal et.al, Lixisenatide-A new Glucagon-like Peptide 1 Receptor Agonist in the treatment of
Type 2 Diabetes. European Endocrinology, 2013,9(2); 76-81. 3. Fonseca, Alvardo-Ruiz, Raccah et al, Efficacy and safety of the Once-Daily GLP-1 Receptor
Agonist Lixisenatide in Monotherapy. Diabetes Care 2012 Jun; 35(6): 1225-31. 4. Ahrén, Dimas, Miossec et al, Efficacy and safety of Lixisenatide Once-Daily
Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care 2013 Sep; 36(9): 2543-50. 5. Riddle, Aronson, Home
et al, Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care 2013 Sep; 36(9) 2489-96.
6. Riddle, Forst, Aronson et al, Adding Once-Daily Lixisenatide for type 2 Diabetes Inadequately Controlled With Newly Initiated and Continously Titrated
Basal Insulin Glargine. Diabetes Care. 2013 Sep; 36(9):2497-503.
Sérlyfjatexti á bls. 61